bioAffinity Technologies, Inc. — Director's Dealing 2022

Dec 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-08-31

Reporting Person: DIAMOND STUART (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-31	Common Stock, par value $0.007	P	4081	—	Acquired	4081	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-31	Warrants (right to buy)	$7.35	P	4081	Acquired	2027-08-31	Common Stock (4081)	Direct
2022-08-31	Non-tradeable Warrants (right to buy)	$7.656	P	4081	Acquired	2027-08-31	Common Stock (4081)	Direct

Footnotes

F1: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2: The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.